Similar Search Results

Foreign direct investment spillovers and pharmaceutical innovation : the role of intellectual property rights

Ho, Chun-Yu; Li, Xin; Zhou, Weimin - 2017

This paper examines the effect of foreign direct investment (FDI) on domestic innovation based on a data set covering … show that there is a negative horizontal spillover effect of FDI on domestic innovation when the intellectual property … on why developing countries should encourage FDI and strengthen the IPR regime together to enhance domestic innovation …

Persistent link: https://www.econbiz.de/10011723712

Biopharma in China : Innovation, Trends and Dealmaking

Agten, Sven; Wu, Ben - 2024

and legal reforms: Gateway to innovation and global integration -- Chapter 3: The golden age of the Chinese biopharma …: Explosive growth in a thriving ecosystem -- Chapter 4: Innovation in the Chinese biopharma: From me-too to First … country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of …

Persistent link: https://www.econbiz.de/10014519028

Invention is a Process, or Why the Electronics and Pharmaceutical Industries are at Loggerheads Over Patents

Dratler, Jay - 2012

The Federal Trade Commission's 2003 innovation report revealed an interesting fact: the pharmaceutical industry is …

Persistent link: https://www.econbiz.de/10014058553

Pharmaceutical Research and Licensing Deals in India

Thomas, Binu - 2016

The global pharmaceutical industry is in an era of greater uncertainty because of looming patent expiries of established drugs having a direct impact on their sales and profitability. Further discovering new drugs in-house is a risky, time consuming and expensive proposition. This has forced...

Persistent link: https://www.econbiz.de/10012994958

Patents, data exclusivity, and the development of new drugs

Gaessler, Fabian; Wagner, Stefan - 2019

Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of the underlying invention (through patents) and the clinical trials data submitted for market approval (through data exclusivity). Patent invalidation during drug development renders data...

Persistent link: https://www.econbiz.de/10012064786

Lo, Andrew W. - 2020

Current business models have struggled to support early-stage drug development. In this paper, we study an alternative financing model, the mega-fund structure, to fund drug discovery. We extend the framework proposed in previous studies to account for correlation between phase transitions in...

Persistent link: https://www.econbiz.de/10012822897

Pharmaceutical spending and early-stage innovation in EU countries

Kourouklis, Dimitrios; Gandjour, Afschin - In: Industry and innovation 29 (2022) 10, pp. 1141-1170

Persistent link: https://www.econbiz.de/10013493053

Launch Decisions of Pharmaceutical Companies

Civan, Abdulkadir - 2016

This paper models the launch decision of pharmaceutical companies in regard to new drugs and country markets. New drugs are launched with a delay or not launched at all in many countries. Considering that many of these new drugs would have created health benefits to the patients, there seems to...

Persistent link: https://www.econbiz.de/10012993196

Mehr Arzneimittel „made in Germany“ über internationale Vernetzung : industriepolitische Handlungsempfehlungen für eine zukunftsfähige Pharmaindustrie

Kirchhoff, Jasmina - 2021

Die Corona-Pandemie hat die deutsche Pharmaindustrie mehr denn je in den Fokus politischer und gesellschaftlicher …

Persistent link: https://www.econbiz.de/10012643455

Enhanced Information Disclosure and Drug Development : Evidence from Mandatory Reporting of Clinical Trials

Hsu, Po-Hsuan - 2020

Using the Food and Drug Administration Amendments Act of 2007 (FDAAA) that requires drug developers to disclose detailed clinical study results publicly, we examine the effect of information disclosure on drug development. We find significantly more suspensions of new drug projects after the...

Persistent link: https://www.econbiz.de/10012847594